Agenus (NASDAQ:AGEN) Stock Price Passes Above 200-Day Moving Average – Time to Sell?

Agenus Inc. (NASDAQ:AGEN)’s stock price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $4.09 and traded as high as $4.38. Agenus shares last traded at $4.25, with a volume of 592,751 shares changing hands.

Analysts Set New Price Targets

Several research analysts have commented on the company. HC Wainwright reissued a “buy” rating and issued a $23.00 price objective on shares of Agenus in a research report on Wednesday, September 10th. Zacks Research raised Agenus to a “hold” rating in a research report on Tuesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Agenus in a research report on Saturday, September 27th. Finally, Wall Street Zen lowered Agenus from a “buy” rating to a “hold” rating in a research report on Sunday, August 17th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $14.50.

Agenus Price Performance

The stock has a fifty day moving average price of $4.51 and a two-hundred day moving average price of $4.09. The company has a market cap of $135.41 million, a P/E ratio of -0.59 and a beta of 1.43.

Agenus (NASDAQ:AGEN) last announced its earnings results on Monday, August 11th. The biotechnology company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.78) by ($0.22). The company had revenue of $25.70 million during the quarter, compared to analysts’ expectations of $49.71 million. As a group, analysts forecast that Agenus Inc. will post -12.55 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC boosted its position in shares of Agenus by 265.9% during the second quarter. Tower Research Capital LLC TRC now owns 21,871 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 15,893 shares in the last quarter. Captrust Financial Advisors bought a new position in shares of Agenus during the second quarter worth $169,000. Engineers Gate Manager LP bought a new position in shares of Agenus during the second quarter worth $108,000. Brevan Howard Capital Management LP bought a new position in shares of Agenus during the second quarter worth $207,000. Finally, Bank of America Corp DE lifted its position in Agenus by 110.0% in the 2nd quarter. Bank of America Corp DE now owns 420,678 shares of the biotechnology company’s stock valued at $1,922,000 after acquiring an additional 220,327 shares in the last quarter. Institutional investors and hedge funds own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.